Britain and America have finalized a significant trade agreement that will keep zero import taxes on UK medicine products going into the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has pledged to raise expenditure on pharmaceuticals through the public health system. This move guarantees that duties on these vital products will stay at nothing for a timeframe of the next three years.
This agreement is in response to earlier warnings to hike duties on branded pharmaceutical imports, with increases mentioned up to 100%.
"This agreement with the United Kingdom reinforces the global environment for cutting-edge drugs and establishes much-needed balance to U.S.–U.K. medicine commerce," a statement said.
Trade Significance
Pharmaceuticals constitute one of the the United Kingdom's largest exports to the America, which is clearly the primary market for large British pharmaceutical firms.
Trade data show that in the one-year period to the end of last September, the UK sold pharmaceutical products worth over eleven billion pounds to the US. This value represented nearly one-fifth of total UK exports in that span.
"This guarantee safeguards employment, increases investment and paves the way for the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary commented.
Specific UK Commitments
The pact entails several notable commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the cost ceiling at which it deems new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a aim to increase overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Payback Limit: The percentage manufacturers must pay back to the NHS to stay within budget will be limited at 15%. In the past, refunds topped 20%.
Broader Context
The pact takes place against a ongoing dispute between the drug companies and the British authorities over drug pricing and NHS adoption.
These tensions were intensified by assertions that US consumers were charged several times more for the same drugs than people in the Britain and the EU.
In recent months, several large manufacturing plans in the UK have been halted or scrapped, while substantial funding commitments have been directed toward American operations.
One official publicly accepted that the NHS had to increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a share of its overall budget over the last ten years.
